NewsRoom Articles - Page 137 of 207

MondayAug 30, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, is moving forward to progress and strengthen its IP portfolio by filing three patents this month. After receiving an international search report of its May 2021 Patent Cooperation Treaty (“PCT”) application, Cybin…

FridayAug 27, 2021 1:33 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Psychedelics date back to ancient times, with records showing their use among the Aztecs as well as cultures in North Africa and Europe for medicinal and cultural purposes The prohibition era marked significant strides in psychedelics research, including the ultimate prohibition of the possession, sale and manufacture of psychedelics The 21st century has seen a surge in psychedelics research, a critical factor that has initiated a renaissance in this industry Tryp Therapeutics remains at the forefront of this renaissance with its commitment to identifying and developing clinical-stage compounds for diseases with high unmet medical needs, like Fibromyalgia and Eating Disorder…

FridayAug 27, 2021 12:54 pm

Study Finds That Sleep Apnea Increases Risk of Sudden Death

Research conducted by Penn State College of Medicine has discovered that individuals who are diagnosed with obstructive sleep apnea have a higher risk of sudden death in comparison with individuals who don’t have sleep apnea. Estimates show that more than one billion people globally suffer from this chronic sleep disorder. The disorder causes a blockage of airflow when an individual is sleeping. This disturbance can also manifest as non-refreshing sleep, heavy snoring, fatigue and excessive daytime sleepiness. The study was published in “BMJ Open Respiratory Research.” The researchers conducted a systematic literature review and identified more than 20 studies focusing…

FridayAug 27, 2021 10:44 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is…

ThursdayAug 26, 2021 12:06 pm

Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

A recently published review has discovered that considering genetic data for individuals who are suffering from drug-resistant focal epilepsy has led to the definition of novel illness entities and enhanced clinical decision making. Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, usually occurs when an individual has failed to stay free of seizures with sufficient trials of 2 ASMs (anti-seizure medication). The disease is often caused by brain lesions such as glioneural tumors. These drugs must have been specifically chosen for the individual’s type of seizures and tried in combination with other seizure medications or on their…

ThursdayAug 26, 2021 10:44 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of…

WednesdayAug 25, 2021 12:31 pm

Study Looks Into Mutations That Cause Resistance to Cancer Therapies

A study conducted by researchers from UT Southwestern has discovered that mutating genes to create proteins that drive cancer using a virus may allow scientists to better understand the resistance that develops to the cancer treatments used to target them. The researchers’ findings were published in “Cancer Research,” with the scientists noting that their discovery could assist in better understanding the interaction between treatments and their target proteins, as well as in the development of treatments that bypass resistance. Dr. Ralf Kittler from the Eugene McDermott Center for Human Growth and Development, who is the research leader, stated that the…

WednesdayAug 25, 2021 11:05 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve British Columbia, Canada-based InMed Pharmaceuticals…

TuesdayAug 24, 2021 12:41 pm

Nearly 30% of Suicide-Prone People Have Regained Full Psychological Well-Being

A nationally representative study that was recently conducted reports that about 29% of participants who had a suicide attempt history had achieved a state of complete mental health. In order to make that determination, participants had to report high levels of psychological and social well-being in the last month, almost daily life satisfaction or happiness in the last month, and freedom from suicidality and mental ailments such as substance dependence and psychiatric disorders to be considered in complete mental health. The study was published in the “Archives of Suicide Research.” Prof. Esme Fuller-Thomson from the University of Toronto, the study’s…

MondayAug 23, 2021 12:05 pm

ASTRO Releases Clinical Guidelines for Soft-Tissue Sarcoma Radiation in Adults

The American Society for Radiation Oncology recently released a new clinical guideline that offers guidance on the utilization of radiation therapy in the treatment of soft-tissue sarcoma patients. The new guideline was published in “Practical Radiation Oncology.” The recommendations include treatment planning, radiation techniques and optimal radiation dosing for patients with operable, localized soft-tissue sarcoma of the extremities, including legs and arms and the abdominal wall and chest wall. Soft-tissue sarcoma is rare, making up only 1% of malignancies in adults. The condition is known to be lethal and comprises more than 50 subtypes, which are all different. The tumors…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), At the Forefront of the Psychedelic Renaissance

Study Finds That Sleep Apnea Increases Risk of Sudden Death

InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference

Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

Study Looks Into Mutations That Cause Resistance to Cancer Therapies

InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels

Nearly 30% of Suicide-Prone People Have Regained Full Psychological Well-Being

ASTRO Releases Clinical Guidelines for Soft-Tissue Sarcoma Radiation in Adults

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search